지투지바이오

456160KOSDAQ

55.8 / 100

Reference Date: 2026-09-08

Financial Score17.5 / 40

News Sentiment21.3 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Slightly up 3.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

GTJ Bio is a leading company in microsphere technology for prolonged-release pharmaceuticals, utilizing its InnoLAMP platform to develop drugs for various diseases and offering CDO/CDMO services. Its key products, including GB-7001, GB-5001, and GB-6002, are undergoing clinical trials in collaboration with global pharmaceutical companies, supported by patented technology and large-scale production capabilities that create high entry barriers.

Number of Employees

48people

Average Salary

125.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

10.92Industry Average 1.200.0Point

9.1x industry avg (risky)

ROE

—Industry Average 8.003.5Point

Debt Ratio

3.69Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2024~20252.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼45.0% (1-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼13.4% (1-year basis)

ROE Trend

2.0 / 4

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 85

Positive
지투지바이오, 장기지속형 치매 치료제 임상1상 결과 초안 수령
지투지바이오의 장기지속형 치매 치료제 GB-5001 임상 1상 결과 초안 수령으로 긍정적인 임상 진행 신호.
Positive
지투지바이오 "치매약 1상서 안전성·내약성 확인"
지투지바이오의 치매 치료제 GB-5001이 임상 1상에서 안전성과 내약성이 확인되어 긍정적인 시장 반응 예상.
Positive
덕수궁 지키는 AI 순찰로봇…3m 밖 화재도 5초 만에 감지
AI 순찰로봇 도입으로 덕수궁 관리 효율성 향상 및 관련 스타트업의 성장 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (16%, downtrend)

Current 38,300Won52-week high 118,80052-week low 22,950

1-month return4.0Point

1m +2.96% (slight rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral투자판단관련주요경영사항(임상시험결과)2026-08-27
Neutral주식등의대량보유상황보고서(일반)2026-08-21
Neutral반기보고서 (2026.06)2026-08-14